All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2022-11-30T15:27:13.000Z

ASH 2022 abstracts: What’s hot in MPN?

By Marta Llobet-Canela, Oscar Williams, Jen Wyatt Green
Featured
Alessandro M. Vannucchi
Steffen Koschmieder
Tiziano Barbui
Nov 30, 2022
Share:

Bookmark this article

To help navigate the exciting content presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee members provided their recommendations for the top presented abstracts in MPN.

Additional publications about the latest data presented at ASH 2022 can be found here.

Top abstracts in MPN

Saturday, December 10, 2022

235

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Jean-Jacques Kiladjian

238

Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

John Mascarenhas

327

Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis

Bridget Marcellino

330

Jak2V617F Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms (MPNs)

Andrew Dunbar

337

Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib

Stephen Oh

340

TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis

Nico Gagelmann

1728

Mediterranean Diet Intervention in Patients with Myeloproliferative Neoplasm

Angela Fleischman

Sunday, December 11, 2022

6

Discovery of INCA033989, a Monoclonal Antibody That Selectively Antagonizes Mutant Calreticulin Oncogenic Function in Myeloproliferative Neoplasms (MPNs)

Edimara Reis

627

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Aaron Gerds

628

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

Stephen Oh

Monday, December 12, 2022

739

Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Claire  Harrison

742

Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Steffen Koschmieder

743

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Trine Knudsen

744

Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial

Tiziano Barbui


ASH2022 abstracts

To download this document, click below.

Download here

More about...
Allo-HSCTAntibody therapyASH 2022CALR driver mutationsEssential thrombocytosisFavorable-riskHigh-riskHydroxyureaIFN-αJAK2 driver mutationsMomelotinibMPN driver mutationsMyelofibrosisMyeloproliferative neoplasmsPacritinibPelabresibPolycythemia veraRiskRuxolitinib

Your opinion matters

What do you consider to be the highest unmet need for patients with myelofibrosis?​
2 votes - 21 days left ...

Related articles

Add bookmark

Timeline of key drug approvals in MPN treatment

Here, we present a visual summary of the key drug approvals for major therapies currently used in the treatment of myeloproliferative neoplasms.

Feb 5, 2024
Add bookmark

Timeline of key drug approvals in MPN treatment

Here, we present a visual summary of the key drug approvals for major therapies currently used in the treatment of myeloproliferative neoplasms.

Feb 5, 2024
Add bookmark

Management of thrombocytopenia in patients with myelofibrosis

Myelofibrosis (MF) is a progressive disease that can either appear de novo (primary MF [PMF]) or occur following a prior diagnosis of essential thrombocythemia (post-ET MF [PET-MF]) or...

Apr 2, 2020
Add bookmark

Management of thrombocytopenia in patients with myelofibrosis

Myelofibrosis (MF) is a progressive disease that can either appear de novo (primary MF [PMF]) or occur following a prior diagnosis of...

Apr 2, 2020

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox